BS_JK0VPG1T
Schwannoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Schwannoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Schwannoma
- overall_survival_months
- 58.27858081471747
- age_years
- 5.477
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.742
- INTERFERON_GAMMA_RESPONSE+0.634
- PROTEIN_SECRETION+0.512
- ALLOGRAFT_REJECTION+0.445
- APOPTOSIS+0.437
- TNFA_SIGNALING_VIA_NFKB+0.419
- OXIDATIVE_PHOSPHORYLATION+0.376
- TGF_BETA_SIGNALING+0.373
- ANDROGEN_RESPONSE+0.370
- ADIPOGENESIS+0.364
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.373
- HEDGEHOG_SIGNALING-0.202
- KRAS_SIGNALING_DN-0.174
- SPERMATOGENESIS-0.169
- E2F_TARGETS-0.157
- MYC_TARGETS_V2-0.109
- G2M_CHECKPOINT-0.086
- MYOGENESIS-0.065
- NOTCH_SIGNALING-0.041
- GLYCOLYSIS+0.043
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HBJZR69P | Schwannoma | — | 0.959 |
| 2 | BS_H3Y8FWHV | Schwannoma | — | 0.935 |
| 3 | BS_CQEETJ66 | Schwannoma | — | 0.935 |
| 4 | BS_NR9FRY5T | Schwannoma | — | 0.930 |
| 5 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.916 |
| 6 | SJEPD031215_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.914 |
| 7 | BS_M9C4RY4P | Schwannoma | — | 0.912 |
| 8 | SRR12696731 | — | — | 0.909 |
| 9 | SRR934811 | — | — | 0.907 |
| 10 | BS_1SVVER1H | Schwannoma | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.742 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.634 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.512 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.445 | Idelalisib | — uncovered |
| APOPTOSIS | 0.437 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.419 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.376 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.373 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.364 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.344 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.341 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.335 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.329 | Idelalisib | — uncovered |
| COMPLEMENT | 0.326 | Inavolisib | — uncovered |
| COAGULATION | 0.318 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.299 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.279 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.277 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.273 | Inavolisib | — uncovered |